ライフサイエンスコーパス: poor adherence

1 to 1.55) were independently associated with poor adherence.

2 ppointing results were attributed largely to poor adherence.

3 Twenty-seven percent of the sample reported poor adherence.

4 s (CIs) identifying barriers associated with poor adherence.

5 s for whom poor asthma control is related to poor adherence.

6 ation schedule were barriers associated with poor adherence.

7 There were five cases of poor adherence.

8 re shown to be an independent risk factor of poor adherence.

9 ucoma medication and factors associated with poor adherence.

10 efined, yet multiple studies have identified poor adherence.

11 oporosis treatments is determining causes of poor adherence.

12 ing medications, even at very high levels of poor adherence.

13 eing gathered regarding processes related to poor adherence.

14 rosis and identifies factors associated with poor adherence.

15 defined as good adherence and 80% or less as poor adherence.

16 65.0%, and 7.7%, respectively) for detecting poor adherence.

17 for inadequate clinical response because of poor adherence.

18 tion for a subset; predictors of good versus poor adherence.

19 models, respectively); (2) persistently very poor adherence (14.9% and 23.4% of persons in the 1- and

20 ents whose imatinib doses were increased had poor adherence (86.4%).

21 iodemographic characteristics helped explain poor adherence (African Americans: low maternal educatio

22 Of these patients, 8 (13%) had poor adherence and 36 (55%) had moderate adherence.

23 poor lung function distinguished those with poor adherence and frequent errors in technique.

24 , failure of prophylaxis was associated with poor adherence and low plasma drug levels.

25 e in actual clinical practice are limited by poor adherence and low prescription rates.

26 ion, it is necessary to analyze the cause of poor adherence and make a concrete action plan.

27 t is lengthy, expensive, and associated with poor adherence and notable morbidity and mortality.

28 mes by not including those at higher risk of poor adherence and reinfection--individuals for whom rea

29 ch that first identifies patients at risk of poor adherence and then seeks to establish the support t

30 gnificant difference between good adherence, poor adherence, and dropout regarding level of understan

31 uate prescription of antiretroviral therapy, poor adherence, and repeated interfaces with congregate

32 Antiviral resistance and poor adherence are the most important factors in treatme

33 Nevertheless, poor adherence but not optimal or improving adherence ca

34 land but is associated with side-effects and poor adherence by patients, and TMP-SMX alone is recomme

35 d survey on factors behind dropout cases and poor adherence cases.

36 Poor adherence contributes to uncontrolled asthma.

37 DH not controlled by gluten-free diet (with poor adherence), dapsone, and conventional immune-suppre

38 regression slopes of viral RNA load for the poor-adherence group were significantly higher than thos

39 herence group), or neither of the above (the poor-adherence group).

40 In the comparison between good and poor adherence groups, except four dropout patients, the

41 ents at risk and to target interventions for poor adherence has increased.

42 ght be a key noninvasive resource to address poor adherence in children and adolescents in a clinical

43 future directions for assessing the risk of poor adherence in clinical settings.

44 s associated with a lower risk of death than poor adherence in patients with CHF, irrespective of ass

45 Factors associated with poor adherence include psychiatric, psychological and em

46 As in adults, poor adherence is the major obstacle to successful conti

47 Identifying factors predicting poor adherence is therefore essential.

48 engthy and onerous, and hence complicated by poor adherence leading to drug resistance and disease re

49 Poor adherence leads to reduced effectiveness, increased

50 sive treatment regimens that compensated for poor adherence led to better improvements in glycemic co

51 th CML treated with imatinib for some years, poor adherence may be the predominant reason for inabili

52 o receive samples will be considered to have poor adherence), misidentification of newly treated pati

53 nately, initial CPAP intolerance may lead to poor adherence or abandonment of therapy.

54 icult as there are no existing biomarkers of poor adherence or inadequate treatment earlier than 2 mo

55 or 100-fold concentration differences due to poor adherence or less frequent prescribed dosing, vagin

56 elect for a resistant subpopulation, whereas poor adherence or second-line therapy resulted in the re

57 ause patients do not take their medications (poor adherence) or because providers do not increase med

58 r deselecting patients with high prior cost, poor adherence, or response to treatments.

59 rved in 60% of cases and was associated with poor adherence (p<0.001) and subsequent development of d

60 ases in efforts to overcome low service use, poor adherence rates, and stigma.

61 chieve HIV RNA suppression by 6 months, with poor adherence, rather than HIV drug resistance, driving

62 th persistent low CD4 cell counts because of poor adherence, resistance to antiretroviral drugs, or b

63 (RR, 6.75; 95% CI, 1.11-70.9; P = .036) and poor adherence (RR, 7.50; 95% CI, 1.23-78.7; P = .026).

64 ns in addressing modifiable risk factors for poor adherence (such as depression, stress, and lower ed

65 occur with oral quinine because of the known poor adherence to 7-d regimens.

66 Poor adherence to a gluten-free diet, HLA-DQ2 homozygosi

67 cholesterolemia) that could be attributed to poor adherence to a healthy lifestyle, we calculated the

68 ng young women that might be attributable to poor adherence to a healthy lifestyle.

69 9% to 89%) of CHD cases were attributable to poor adherence to a healthy lifestyle.

70 We considered the factors of poor adherence to and dropout from sublingual immunother

71 od, hygiene, and shelter needs), followed by poor adherence to antiretroviral therapy, not having a c

72 Poor adherence to antiretroviral treatment regimens has

73 Poor adherence to both corticosteroids predicted signifi

74 that IPs reported inadequate drug provision, poor adherence to clinical national guidelines, and that

75 symptoms can be poorly controlled because of poor adherence to controller therapy, and this might be

76 tions may be acceptable to veterans who have poor adherence to existing evidence-based treatments for

77 In conclusion, poor adherence to hemodialysis treatments may be a subst

78 Poor adherence to HIV protease inhibitors may compromise

79 Factor A was defined as poor adherence to ICS or ICS/LABA inhaler of 75% or less

80 We suggest that poor adherence to insulin treatment is the major factor

81 Poor adherence to medication is common in some chronic i

82 l or other drug abuse problems combined with poor adherence to medication may signal a higher risk of

83 Poor adherence to medication regimens is common, potenti

84 Poor adherence to medication regimens may be contributin

85 e term hypertension or its cause, leading to poor adherence to medications and limiting other effecti

86 Fifty-eight percent of patients exhibited poor adherence to prescribed antihypertensive medication

87 Poor adherence to prescribed therapies is common in pati

88 We find that poor adherence to such drugs causes treatment failure vi

89 ute to ineffective cancer pain management is poor adherence to the analgesic regimen.

90 Subtherapeutic drug levels can be caused by poor adherence to the drug regimen, interactions with ot

91 trials have reported varying efficacy due to poor adherence to the drug.

92 se aspects of care; however, physicians show poor adherence to the guidelines despite the evidence th

93 Plasma tenofovir concentrations demonstrated poor adherence to the study product among study subjects

94 eral prescription medications sometimes have poor adherence to their treatment regimens.

95 (<8.0 g/dL; AHR, 3.1; 95% CI, 2.3-4.0), and poor adherence to therapy (AHR, 2.9; 95% CI, 2.2-3.9).

96 Poor adherence to therapy makes it unlikely that the sig

97 Presence of FNf did not reflect poor adherence to therapy.

98 nderutilization of therapy by providers, and poor adherence to treatment among patients.

99 Poor adherence to treatment diminishes its individual an

100 Poor adherence to treatment may be one of the mechanisms

101 provider reliance on clinical diagnosis and poor adherence to treatment policy, especially in first

102 dy fat, which leads to further morbidity and poor adherence to treatment.

103 Poor adherence was a major determinant of virological fa

104 Poor adherence was defined as adherence of less than 50%

105 Factors associated with poor adherence were less than 12 yr of formal education

106 utcome variability, especially the impact of poor adherence, which is critical to manage PrEP in the

107 in patients with cystic fibrosis, indicating poor adherence, which is particularly common in adolesce

108 ble for isoniazid preventive therapy and the poor adherence with a complete regimen among those we in

109 een associated with poor quality of life and poor adherence with antiretroviral therapy.

110 ack of health insurance, and no access to or poor adherence with controller medications such as inhal

111 nt to at least 30% of surveyed patients with poor adherence, with most identifying multiple barriers

112 Poor adherence, younger age, and more comorbidities were